Optimized Polyepitope Neoantigen DNA Vaccines Elicit Neoantigen-Specific Immune Responses in Preclinical Models and in Clinical Translation
Demographics (3)
- AGE - Subject age at enrollment (phv00482693.v1.p1)
- COLLECTION_AGE - Age sample was collected (phv00482699.v1.p1)
- SEX - Biological sex (phv00482688.v1.p1)
Disease Events (3)
- HISTOLOGICAL_TYPE - Histological type (phv00482698.v1.p1)
- IS_TUMOR - Tumor status (phv00482697.v1.p1)
- PRIMARY_TUMOR_LOCATION - Primary tumor location (phv00482701.v1.p1)
Race and Ethnicity (1)
- RACE - Self-reported race (phv00482692.v1.p1)
Other (9)
- ANALYTE_TYPE - Analyte type (phv00482696.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00482695.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00482687.v1.p1)
- PRIMARY_METASTATIC_TUMOR - Primary tumor, metastasis, or transformed cell line (phv00482700.v1.p1)
- SAMPLE_ID - Sample ID (phv00482694.v1.p1)
- SAMPLE_ID - Sample ID (phv00482690.v1.p1)
- SUBJECT_ID - Subject ID (phv00482686.v1.p1)
- SUBJECT_ID - Subject ID (phv00482691.v1.p1)
- SUBJECT_ID - Subject ID (phv00482689.v1.p1)